HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Bank of America Healthcare Conference in Las Vegas, NV.

加利福尼亚州海沃德（商业新闻短讯）--Arcus Biosciences（纽约证券交易所：RCUS），一家临床阶段的全球生物制药公司，专注于为癌症患者开发分化分子和联合疗法，宣布其管理团队将参加即将在内华达州拉斯维加斯举行的美国银行医疗保健会议的炉边聊天。

The fireside chat will take place on Thursday, May 16th, 2024 at 10:00am PT..

炉边聊天将于2024年5月16日星期四上午10:00举行。。

A live webcast of the fireside chat will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay will be available following the live event.

通过访问Arcus Biosciences网站www.arcusbio.com的“投资者与媒体”部分，可以在线直播炉边聊天。现场活动后将提供重播。

About Arcus Biosciences

关于Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer.

Arcus Biosciences是一家临床阶段的全球生物制药公司，为癌症患者开发分化分子和联合药物。与世界各地的行业合作者、患者和医生合作，Arcus正在加速开发一流或一流的药物，以对抗特征明确的生物靶标和途径，并研究新颖的生物学驱动的组合，这些组合有可能帮助癌症患者活得更长。

Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com..

该公司成立于2015年，加快了多种研究药物进入临床研究的发展，包括针对TIGIT，PD-1，腺苷轴（CD73和双A2a/A2b受体），HIF-2a，CD39和AXL的新组合方法。有关Arcus Biosciences临床和临床前项目的更多信息，请访问www.arcusbio.com。。